

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

Claims 1-16 (canceled)


Claim 17 (currently amended): A compound of formula 1:



wherein **Ar**¹ is



wherein **R**¹² is selected from the group consisting of



R¹³ represents Cl, Br, COO(C₁₋₄)alkyl and
if R⁹ is NO₂, Cl or Br, then R¹³ may also represent F or CH₃;

R¹⁴, **R**¹⁵,

R³¹, **R**³²,


R³³ are each independently selected from the group consisting of H, (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl-(C₁₋₃)alkyl, (C₂₋₆)alkenyl, O-(C₁₋₄)alkyl, S-(C₁₋₄)alkyl, halo, CF₃, OCF₃, OH, NO₂, CN, SO₂NH₂, SO₂-(C₁₋₄)alkyl, C(O)OR¹ wherein R¹ is H or (C₁₋₄)alkyl, or NR²R³ wherein R² and R³ each independently is H or (C₁₋₄)alkyl;

R³⁰ represents H, Cl, Br, COO(C₁₋₄)alkyl; and

X is S or O;

W is CH₂C(O)NR⁶ wherein R⁶ is H or (C₁₋₄)alkyl; and

Ar² is selected from the group consisting of




wherein R⁹ is halo or NO₂; and if R¹³ is Cl or Br, then R⁹ may also represent (C₁₋₃)alkyl;

R¹⁰, R¹¹ are independently of each other selected from the group consisting of H, (C₁₋₆)alkyl, (C₃₋₇)Cycloalkyl, (C₃₋₇)Cycloalkyl-(C₁₋₃)alkyl, (C₂₋₆)alkenyl, O(C₁₋₆)alkyl, S(C₁₋₆)alkyl, halo, CF₃, OCF₃, OH, NO₂, CN, -NR^{N1}R^{N2}, -C(O)R²¹, -(C₁₋₃)alkyl-C(O)R²¹, -C(O)OR²², -(C₁₋₃)alkyl-C(O)OR²², -SO₂-(C₁₋₃)alkyl-C(O)OR²², wherein R²¹ is (C₁₋₄)alkyl and R²² is H or (C₁₋₄)alkyl; -(C₁₋₃)alkyl-C(O)NH₂, C(O)NH₂, S(O)-(C₁₋₆)alkyl, -SO₂-(C₁₋₆)alkyl, -SO₂-phenyl, -SO₂-NH₂, phenyl, phenylmethyl, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo, NO₂, C₁₋₃-alkyl and CF₃;

wherein R^{N1}, R^{N2} each independently represent H or (C₁₋₆)alkyl, whereby R^{N1} and R^{N2} may be covalently bonded to each other to form together with the N-atom to which they are attached to a 4 to 7-membered heterocycle whereby the -CH₂- group at the position 4 of a 6 or 7-membered heterocycle may be replaced by -O-, -S- or -NR^{N3}- wherein R^{N3} represents H, -C(O)OR²², (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl or (C₃₋₇)cycloalkyl-(C₁₋₃)alkyl, wherein R²² is H or (C₁₋₄)alkyl;


or a pharmaceutically acceptable salt thereof.

Claim 18 (previously presented): The compound of formula 1 according to claim 17 wherein \mathbf{Ar}^1 is



; and

wherein \mathbf{R}^{12} is selected from the group consisting of



wherein \mathbf{R}^{13} , \mathbf{R}^{14} , \mathbf{R}^{15} , \mathbf{R}^{30} , \mathbf{R}^{31} , \mathbf{R}^{32} and \mathbf{R}^{33} are as defined in claim 17.

Claim 19 (original): The compound of formula 1 according to claim 18 wherein

\mathbf{R}^{13} represents Cl or Br and

if \mathbf{R}^9 is NO_2 , Cl or Br, then \mathbf{R}^{13} may also represent F or CH_3 ;

\mathbf{R}^{14} , \mathbf{R}^{15} ,

\mathbf{R}^{31} , \mathbf{R}^{32} ,


\mathbf{R}^{33} are each independently selected from the group consisting of H, $(\text{C}_{1-6})\text{alkyl}$, $(\text{C}_{3-7})\text{cycloalkyl}$, $(\text{C}_{3-7})\text{cycloalkyl-(C}_{1-3}\text{)alkyl}$, $(\text{C}_{2-6})\text{alkenyl}$, $\text{O-(C}_{1-4}\text{)alkyl}$, $\text{S-(C}_{1-4}\text{)alkyl}$, halo, CF_3 , OCF_3 , OH, NO_2 , CN, SO_2NH_2 , $\text{SO}_2(\text{C}_{1-4})\text{alkyl}$, C(O)OR^1 wherein \mathbf{R}^1 is H or $(\text{C}_{1-4})\text{alkyl}$, or $\text{NR}^2\mathbf{R}^3$ wherein \mathbf{R}^2 and \mathbf{R}^3 each independently is H or $(\text{C}_{1-4})\text{alkyl}$; and

\mathbf{R}^{30} represents Cl or Br.

Claim 20 (original): The compound of formula 1 according to claim 19 wherein \mathbf{W} is



$\text{CH}_2\text{C(O)NH}$.

Claim 21 (original): A compound according to claim 17 wherein




\mathbf{Ar}^1 is defined as and

wherein \mathbf{R}^{12} is selected from the group consisting of




wherein R⁹ is halo or NO₂; or

Ar² is



wherein R⁹ is halo or NO₂ and R¹⁰ is halo; or


Ar² is




wherein R⁹ is halo or NO₂, and R¹⁰ is OMe, halo, OH, NO₂, phenyl, C(=O)OH or C(=O)OMe.

Claim 22 (canceled)


Claim 23 (original): A compound of formula 1, according to claim 17, wherein Ar^1 is:



and wherein R^{12} selected from the group consisting of:




And



Claim 24 (canceled)

Claim 25 (currently amended): A compound of formula 1, according to claim 17, wherein

Ar² is selected from the group consisting of



wherein **R⁹** is Cl or NO₂ and


R^{10A} is C₁₋₄alkyl;


R¹⁰ is selected from the group consisting of (C₁₋₄)alkyl, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl-(C₁₋₃)alkyl, (C₂₋₆)alkenyl, O(C₁₋₆)alkyl, S(C₁₋₆)alkyl, halo, CF₃, OCF₃, OH, NO₂, CN, -NR^{N1}R^{N2}, -C(O)R²¹, -(C₁₋₃)alkyl-C(O)R²¹, -C(O)OR²², -(C₁₋₃)alkyl-C(O)OR²², -SO₂-(C₁₋₃)alkyl-C(O)OR²², -(C₁₋₃)alkyl-C(O)NH₂, C(O)NH₂, -S(O)-(C₁₋₆)alkyl, -SO₂-(C₁₋₆)alkyl, -SO₂-phenyl, -SO₂-NH₂, phenyl, phenylmethyl, phenyl-SO₂-, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo, NO₂, C₁₋₃-alkyl and CF₃;

wherein **R²¹** is (C₁₋₄)alkyl and **R²²** is H or (C₁₋₄)alkyl;

wherein **R^{N1}**, **R^{N2}** each independently represent H or (C₁₋₆)alkyl, whereby **R^{N1}** and **R^{N2}** may be covalently bonded to each other to form together with the N-atom to which they are attached to a 4 to 7-membered heterocycle whereby the -CH₂-group at the position 4 of a 6 or 7-membered heterocycle may be replaced by -O-, -S- or -NR^{N3}- wherein **R^{N3}** represents H, -C(O)OR²², (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl or (C₃₋₇)cycloalkyl-(C₁₋₃)alkyl, wherein **R²²** is H or (C₁₋₄)alkyl.

Claim 26 (original): A compound of formula 1, according to claim 25, wherein **Ar²** is:





Claim 27 (canceled)

Claim 28 (original): A pharmaceutical composition comprising a compound of formula 1 as defined in claim 17, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers.

Claim 29 (canceled)

Claim 30 (original): A pharmaceutical composition for the treatment of HIV infection, comprising a compound of formula 1 as defined in claim 17, or a pharmaceutically acceptable salt thereof.

Claim 31 (canceled)